Beclomethasone rapidly ablates allergen-induced beta 2-adrenoceptor pathway dysfunction in human isolated bronchi

Area of Science:

• Pharmacology
• Respiratory Medicine
• Cellular Signaling

Background:

• Allergen challenge in asthma leads to beta(2)-adrenoceptor (beta(2)-AR) pathway dysfunction.
• This dysfunction impairs the relaxant effects of beta(2)-AR agonists like salbutamol.
• The underlying mechanisms of this impaired signaling pathway require further elucidation.

Purpose of the Study:

• To investigate the effect of beclomethasone dipropionate (BDP) on allergen-induced beta(2)-AR pathway dysfunction in human bronchi.
• To determine the specific molecular mechanisms by which BDP restores beta(2)-AR function.

Main Methods:

• Human bronchial rings from nonatopic donors were sensitized with allergic serum.
• Rings were challenged with allergen, and the effects of salbutamol and carbachol were measured.
• Treated rings were incubated with beclomethasone dipropionate (BDP) for 3 hours.
• Cholera toxin and forskolin were used to probe specific components of the signaling pathway.
• G(s)alpha protein expression and activity were assessed.

Main Results:

• Allergen challenge significantly reduced the relaxant effect of salbutamol, indicating beta(2)-AR pathway dysfunction.
• Short-term BDP treatment (3 hours) restored the relaxant response to salbutamol.
• BDP treatment increased the activity of G(s)alpha protein without altering its expression.
• The dysfunction was localized proximal to adenylyl cyclase, as forskolin-induced relaxation was unaffected.

Conclusions:

• Short-term treatment with beclomethasone dipropionate effectively reverses allergen-induced beta(2)-AR pathway dysfunction in human bronchi.
• This reversal is mediated by an increase in G(s)alpha protein activity.
• These findings highlight a rapid mechanism for corticosteroid action in restoring beta(2)-AR signaling in allergic airways.